Harrow (HROW) Share-based Compensation Growth (1y) (2011 - 2026)
Harrow (HROW) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 5.26% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -36.59% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -0.11% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | -49.74% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -18.06% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 23.11% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -65.00% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn | 332.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 332.91% |
| Mar 31, 2026 | -15.78% |
| Dec 31, 2025 | -20.73% |
| Sep 30, 2025 | -25.43% |
| Jun 30, 2025 | -79.51% |
| Mar 31, 2025 | 9.28% |
| Dec 31, 2024 | 14.83% |
| Sep 30, 2024 | -2.03% |
| Jun 30, 2024 | -21.08% |
| Mar 31, 2024 | 155.30% |
| Dec 31, 2023 | -27.84% |
| Sep 30, 2023 | 131.68% |
| Jun 30, 2023 | 171.55% |
| Mar 31, 2023 | 57.63% |
| Dec 31, 2022 | 173.57% |
| Sep 30, 2022 | 13.85% |
| Jun 30, 2022 | 84.88% |
| Mar 31, 2022 | 21.17% |
| Dec 31, 2021 | 203.44% |
| Sep 30, 2021 | 85.06% |